We are live on ! Find out more
EAM

Erste Asset Management Portfolio holdings

AUM $12.9B
1-Year Est. Return 52.69%
This Fund
S&P 500
This Quarter Est. Return
+8.41%
1 Year Est. Return
+52.69%
3 Year Est. Return
+142.55%
5 Year Est. Return
+182.36%
10 Year Est. Return
AUM
$5.55B
AUM Growth
+$502M
Cap. Flow
+$232M
Cap. Flow %
4.18%
Top 10 Hldgs %
19.68%
Holding
571
New
51
Increased
198
Reduced
144
Closed
33

Top Buys

Rank Stock Value
1
RUN icon
Sunrun
RUN
+$26.1M
2
CTAS icon
Cintas
CTAS
+$23.1M
3
NOVA
Sunnova Energy
NOVA
+$18.6M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$17.5M
5
DQ
Daqo New Energy
DQ
+$14M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$23.6M
2
SIMO icon
Silicon Motion
SIMO
+$20.7M
3
CMCSA icon
Comcast
CMCSA
+$17M
4
V icon
Visa
V
+$16.6M
5
TJX icon
TJX Companies
TJX
+$13.3M

Sector Composition

Rank Sector Weight
1 Technology 31.13%
2 Healthcare 18.96%
3 Consumer Discretionary 13.96%
4 Financials 9.3%
5 Industrials 7.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CFG icon
451
Citizens Financial Group
CFG
$29.6B
$343K 0.01%
+7,247
New +$349K
CHTR icon
452
Charter Communications
CHTR
$16.8B
$342K 0.01%
+521
New +$355K
PCVX icon
453
Vaxcyte
PCVX
$8.81B
$341K 0.01%
14,200
IVZ icon
454
Invesco
IVZ
$13.6B
$337K 0.01%
+14,414
New +$351K
ADAP
455
DELISTED
Adaptimmune Therapeutics
ADAP
$333K 0.01%
90,000
AGCO icon
456
AGCO
AGCO
$8.67B
$331K 0.01%
+2,855
New +$347K
WFG icon
457
West Fraser Timber
WFG
$5.6B
$319K 0.01%
3,350
REPL icon
458
Replimune Group
REPL
$1.23B
$318K 0.01%
11,900
KROS icon
459
Keros Therapeutics
KROS
$221M
$318K 0.01%
5,700
PVH icon
460
PVH
PVH
$3.3B
$317K 0.01%
+3,000
New +$328K
SGMO
461
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$301K 0.01%
38,000
AFYA icon
462
Afya
AFYA
$1.21B
$293K 0.01%
19,191
-6,250
-25% -$100K
MGNX icon
463
MacroGenics
MGNX
$257M
$286K 0.01%
18,000
LNC icon
464
Lincoln National
LNC
$8.32B
$282K 0.01%
4,100
-2,200
-35% -$155K
AFG icon
465
American Financial Group
AFG
$11.9B
$278K 0.01%
2,000
-1,700
-46% -$234K
CMRX
466
DELISTED
Chimerix, Inc.
CMRX
$270K ﹤0.01%
+40,000
New +$240K
SRRK icon
467
Scholar Rock
SRRK
$6.09B
$266K ﹤0.01%
10,300
AIZ icon
468
Assurant
AIZ
$14.1B
$263K ﹤0.01%
1,700
-700
-29% -$111K
PSTH
469
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
$261K ﹤0.01%
13,250
+600
+5% +$11.9K
FICO icon
470
Fair Isaac
FICO
$21.3B
$260K ﹤0.01%
600
MKL icon
471
Markel Group
MKL
$22.2B
$248K ﹤0.01%
200
-200
-50% -$252K
WRB icon
472
W.R. Berkley
WRB
$26.5B
$248K ﹤0.01%
6,750
-11,430
-63% -$405K
ARCT icon
473
Arcturus Therapeutics
ARCT
$450M
$241K ﹤0.01%
6,200
MCRB icon
474
Seres Therapeutics
MCRB
$46.2M
$235K ﹤0.01%
1,350
ARQT icon
475
Arcutis Biotherapeutics
ARQT
$2.96B
$227K ﹤0.01%
11,100

Similar funds

Erste Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Erste Asset Management held 571 positions worth $5.55B, up 9.9% from $5.05B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Erste Asset Management deployed $232M of net new capital in Q4 2021, opening 51 new positions and adding to 198 existing holdings. Its largest new stake was Cintas: 214,128 shares worth $23.7M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was NVIDIA, an estimated $23.6M trimmed.

  • Erste Asset Management's largest Q4 2021 buy was Cintas: 214,128 shares worth $23.7M.
  • Erste Asset Management added most to Sunrun in Q4 2021, an estimated $26.1M increase.
  • Erste Asset Management's biggest Q4 2021 reduction was NVIDIA, cutting an estimated $23.6M.
  • Erste Asset Management fully exited Advanced Energy in Q4 2021, selling an estimated $8M.
  • Erste Asset Management's ten largest holdings make up 20% of its $5.55B portfolio in Q4 2021.
  • Erste Asset Management opened 51 new positions and closed 33 in Q4 2021.
  • Erste Asset Management's portfolio value rose 9.9% quarter-over-quarter to $5.55B.

Based on Erste Asset Management's 13F filing for Q4 2021, filed 25 Nov 2024.